Cynata Therapeutics Ltd., of Melbourne, Australia, reported data from the first cohort of eight patients in its phase I trial testing CYP-001, a Cymerus mesenchymal stem cell product, who received 1 million cells per kilogram of bodyweight, up to a maximum of 100 million cells per infusion, for the treatment of steroid-resistant graft-vs. host disease (GvHD).